RxDoctor Payments Data

Doney Jain, MD

Internal Medicine · Jersey City, NJNPI 1720484777

Payments from drug & device makers

$1,323in general payments, 2019–2025

Across 66 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$214
  • Otsuka America Pharmaceutical, Inc.$194
  • Kerecis Limited$193
  • E.r. Squibb & Sons, L.L.C.$123
  • Braeburn Inc.$94
  • Pfizer$73
  • plus $432 from 16 others

What the payments were for

  • Food & beverage$1,323100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,323 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$334,093
Medicare patients
296
Services billed
3,565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban620$160,416
Invega SustennaPaliperidone Palmitate37$136,325
NuplazidPimavanserin Tartrate19$47,226
Divalproex Sodium601$35,819
XareltoRivaroxaban169$33,977
Risperdal ConstaRisperidone Microspheres20$26,244
TrulicityDulaglutide27$25,242
JanuviaSitagliptin Phosphate73$20,660
Incruse ElliptaUmeclidinium Bromide45$17,193
CaplytaLumateperone Tosylate16$13,264
LinzessLinaclotide23$12,583
XiidraLifitegrast16$11,987
Atorvastatin Calcium899$11,699
Oxcarbazepine98$10,112
VascepaIcosapent Ethyl54$10,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto, Risperdal Consta$13$196,547226 claims
PfizerEliquis, Retacrit$73$164,788633 claims
Lilly USA, LLCTrulicity$15$25,24227 claims
AbbVieLinzess, Restasis$14$20,69343 claims
NovartisEntresto$30$6,89020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Jersey City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →